Search research articles
Contact Us
Filters
Showing results (131-140 of 234) with videos related to
Page
of 24
Sort By:
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
April 27, 2017
<i>Supplementary data:</i> Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer
Victor A McPherson, George Rodrigues, Glenn Bauman, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
April 10, 2018
Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel
Daniel W Yokom, John Stewart, Nimira S Alimohamed, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
May 25, 2016
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone
Fred Saad, Eric Winquist, Stacey Hubay, et al.
Medicine
|
August 20, 2015
A Population-Based Study of 30-day Incidence of Ischemic Stroke Following Surgical Neck Dissection
S Danielle MacNeil, Kuan Liu, Amit X Garg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2010
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
Joaquim Bellmunt, Toni K Choueiri, Ronan Fougeray, et al.
Clinical Chemistry
|
March 28, 2009
New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs
Pieter H Anborgh, Sylvia M Wilson, Alan B Tuck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 26, 2017
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion
Katherine S Virgo, Ethan Basch, D Andrew Loblaw, et al.
Investigational New Drugs
|
March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
Srikala S Sridhar, Eric Winquist, Andrea Eisen, et al.
The Oncologist
|
November 7, 2015
Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer
Urban Emmenegger, Christopher M Booth, Scott Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
Fred Saad, Sebastien Hotte, Scott North, et al.
Page
of 24
Search research articles
Search
Showing results (131-140 of 234) with videos related to
Sort By:
Page
of 24
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
April 27, 2017
<i>Supplementary data:</i> Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer
Victor A McPherson, George Rodrigues, Glenn Bauman, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
April 10, 2018
Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel
Daniel W Yokom, John Stewart, Nimira S Alimohamed, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
May 25, 2016
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone
Fred Saad, Eric Winquist, Stacey Hubay, et al.
Medicine
|
August 20, 2015
A Population-Based Study of 30-day Incidence of Ischemic Stroke Following Surgical Neck Dissection
S Danielle MacNeil, Kuan Liu, Amit X Garg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2010
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
Joaquim Bellmunt, Toni K Choueiri, Ronan Fougeray, et al.
Clinical Chemistry
|
March 28, 2009
New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs
Pieter H Anborgh, Sylvia M Wilson, Alan B Tuck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 26, 2017
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion
Katherine S Virgo, Ethan Basch, D Andrew Loblaw, et al.
Investigational New Drugs
|
March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
Srikala S Sridhar, Eric Winquist, Andrea Eisen, et al.
The Oncologist
|
November 7, 2015
Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer
Urban Emmenegger, Christopher M Booth, Scott Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
Fred Saad, Sebastien Hotte, Scott North, et al.
Page
of 24